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Abstract:  Lyme  disease  is  one  of  the  most  frequent  tick-borne  diseases  worldwide,  it  can  be  multi-systemic  and  insidious,  in
particular when it shows a chronic course.
In recent years co-infections represent an emerging issue in Lyme disease spectrum because in addition to Borrelia burgdorferi sl
many other potential pathogens may be transmitted by hard ticks Ixodes species. The main co-infections found in Lyme disease
described in this review are represented by Anaplasma phagocytophilum, Babesia species, Bartonella species, Rickettsiae species
and tick-borne encephalitis virus. For each single co-infecting micro-organism, clinical features, diagnostic issues and therapeutical
approaches are discussed.
Co-infections represent an emerging problem because they might exacerbate Lyme disease clinical features, they can also mimic
Lyme borreliosis sharing common manifestations, and eventually they can change the course of the disease itself.
The presence of one or more co-infecting agent during the course of Lyme disease may represent an issue especially in endemic areas
for tick-borne diseases and in people occupationally exposed.
The  aim  of  this  review  is  to  summarize  the  more  important  co-infections  in  patients  with  Lyme  disease  and  to  discuss  their
importance in the disease process.
Keywords: Anaplasma phagocytophilum, Babesia species, Bartonella species, Borrelia burgdorferi, Co-infections, Lyme disease,
Rickettsiae species, Tick-borne encephalitis virus.
INTRODUCTION
Lyme disease (LD) is one of the commonest vector-borne infections worldwide, caused by a spirochete, Borrelia
burgdorferi sensu lato (Bb), and transmitted to humans through hard tick (Ixodes spp.) bite [1, 2]. In addition to Bb,
other  human pathogens may be transmitted by Ixodes  ticks [3].  A concomitant  infection of  more than one agent  is
named  co-infection.  The  risk  for  human  co-infections  with  multiple  pathogens  after  an  Ixodes  tick  bite  differs  by
geographic location and depends on the prevalence of pathogens within the reservoir host and Ixodes ticks [4 - 6]. The
more relevant co-infections in LD are caused by Anaplasma phagocytophilum, Babesia species, Bartonella species,
primary Bartonella hensalae and tick-borne encephalitis virus (TBEV) [5]. Bartonella henselae is the aetiologic agent
of cat scratch disease, which is not transmitted to humans by ticks.
The  clinical  and  pathological  impact  of  co-infections  was  first  recognized  in  1990,  about  ten  years  after  the
discovery of LD and they are thought to be the main reason for treatment failures [7].
Co-infections might exacerbate LD as well as they can induce similar clinical manifestations or change the course of
the disease [3, 4, 7, 8]. However the actual burden of co-infections in the natural disease history has not been unravelled
yet. When two or more pathogens infect a patient, clarifying which is the major responsible of the clinical pictures can
be challenging, since LD can share common clinical features with other conditions transmitted by Ixodes ticks bite
especially in early stages [3,  9,  10].  The difficulties in diagnosis and management of co-infections in LD are more
related to late and chronic LD since co-infecting agents might cause chronic forms of diseases too [3, 7].
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In such cases an accurate anamnestic report in early stages may be useful to recognize the chronic course of the co-
infection together with LD.
The diagnosis of co-infections is based on patient’s history, the course of the disease, results of medical technical
tests, physical examination and the exclusion of differential diagnoses.
Laboratory tests for diagnosis of LD and co-infecting agents are available both for serology, culture and indirect
detection by lymphocyte transformation test [11, 12]. The most widely used and reliable test is the two-step serological
diagnosis  with  the  confirmation  by  Western  blot  in  case  of  positive  or  doubtful  serology.  Serological  findings,
especially in endemic areas, are not always signs of the current infection and a negative serology is not sufficient to
exclude the disease [13, 14]. The positive serological result only proofs that infection has taken place, but cannot prove
the disease and there may be seronegativity in case of co-infection with long lasting chronic disease.
Since the treatment of the infections caused by various tick-borne pathogens differs from one another, concomitant
infections are becoming a serious epidemiological and clinical problem [15].
The aim of this review is to summarize the most important co-infections in patients with LD and to discuss their
importance in the disease process.
ANAPLASMA PHAGOCYTOPHILUM
Tick-borne  Rickettsiae  in  the  genera  Ehrlichia  and  Anaplasma  are  intracellular  bacteria  that  infect  wild  and
domestic  mammals  and  humans.  They  can  cause  human  granulocitic  anaplasmosis  (HGA),  an  acute  febrile  illness
ranging from asymptomatic to severe disease in humans [16]. The main features of HGA are fever, headache, joint and
muscle pain and laboratory findings such as leukopenia, thrombocytopenia and high liver enzymes levels in peripheral
blood.  Usually  the  infection  is  mild  and  self-limiting,  even  if  it  can  be  life-threatening  with  the  development  of
meningitis and other central nervous system disorders. The incubation period is about 7 days from the tick bite and the
development of symptoms. Co-infection between LD and HGA ranges from 2% to 11% in three studies [4, 3, 17, 18].
In a recent study Strle et  al.  demonstrated that  in Slovenia,  a country endemic for LD, TBE and HGA, none of 67
patients involved in the survey with typical erythema migrans was found to be co-infected with A. phagocytophilum,
even if only serology was performed by the Authors as diagnostic tool [19].
In 2007, Grab et al. found that the infection of A. phagocytophilum may be responsible of a more severe form of LD
with  enhanced  dissemination  and  possible  long-term  complications  because  co-infection  causes  reduction  in
transendothelial electric resistance and increased production of metalloproteinases, cytokines and chemokines [20, 21].
Recently, Horowitz et al. analysed patients having erythema migrans and a positive blood culture for Anaplasma
phagocytophilum living in Valhalla, New York. They found that the total number of symptoms was not significantly
different in patients with LD alone and patients with LD and HGA. In addition to that, the Authors interestingly noted
that patients having HGA alone experienced a shorter duration of illness compared with those co-infected by Bb and
Anaplasma  phagocytophilum,  maybe  because  they  went  sooner  to  the  doctor.  In  this  study  leukopenia  and
thrombocytopenia were reported more frequently in HGA alone than in co-infections, even if this difference was not
statistically significant [15]. In Literature conflicting data about the severity of co-infection compared to LD or HGA
alone are available [7, 10, 17, 18].
The diagnosis of HGA is mostly based on serology findings: specific antibodies can be detected two to three weeks
after the onset of the illness. Anaplasma phagocytophilum can also be amplified by means of PCR from the blood or it
can be cultured from blood as well. Eventually intragranulocitic morulae can be directly detected from peripheral blood
stained with Giemsa and observed under microscope [4, 15, 22].
Doxycycline 100 mg twice a day is found to be the most effective therapy, it can be the treatment of choice also in
children [3, 4]. Usually it is prescribed orally for 14 days, but no universal data are available [4, 15, 23].
Rifampicin and possibly levofloxacin may be second choice treatments: they showed good antimicrobial activity in
vitro, but clinical studies are poor or lacking. Anaplasma phagocytophilum has found to be resistant to several classes of
antibiotics  such  as  amoxicillin  and  other  beta-lactams,  erythromycin,  azithromycin,  clarithromycin,  clindamycin,
trimethoprim-sulfamethoxazole [3, 24, 25].
BABESIA SPECIES
Human babesiosis is a tick-borne disease, caused primarily by the intraerythrocytic protozoan Babesia microti and
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by other Babesia species. In the United States Babesia microti has found to be more often detected in ticks, whether in
Europe Babesia divergens seemed to be prevalent [6, 8, 11, 26]. It can be transmitted either by Ixodes ticks or less often
with blood transfusions and by perinatal infection. The clinical spectrum of the infection ranges from asymptomatic or
moderate disease to rapidly progressive and sometimes fatal [4, 11]. Acute Babesiosis usually shows as fever and flu-
like symptoms such as myalgia, chills, gastro-intestinal features. Since Babesia causes an intra-erythrocytic infection,
haemolysis  ranging  with  different  severity  can  be  detected  as  well.  Immunocompromised  subjects  as  oncologic,
asplenic and undergoing immunosuppressive therapy patients could develop a more severe disease form which might
become chronic and relapsing [27].
Babesia  infection can be proved with DNA amplification by means of PCR. It  can be detected also with direct
confirmation of the protozoan on blood smear, but this technique is not straightforward and usually requires multiple
examinations. Serology is not helpful because it is poorly associated with clinical symptoms, especially in endemic
areas [28, 29].
Studies of clinical outcomes suggest that patients with acute Babesia co-infection have more severe symptoms and a
longer duration of illness than patients with LB alone, but the risk of spirochete dissemination seems to be similar [7].
Concomitant infections may be difficult to diagnose since both LD and Babesiosis have overlapping symptoms e.g.
flu-like illness with fever and fatigue [20].
In  Literature  atovaquone,  azithromycin,  clindamycin  with  or  without  quinine  are  found  to  be  effective  [15].
Clindamycin 600 mg every 8 hours taken orally plus quinine 650 mg orally every 8 hours for 7 to 10 days have efficacy
proven in Literature in milder forms of disease [30, 31], while the intravenous use of clindamycin is preferred in more
severe disease forms. Alternative and similarly effective treatments are atovaquone 750 mg twice daily taken orally plus
azithromycin 250 mg daily except for the fisrt day of treatment (500 mg) for 7 days as well. These therapies have to be
associated with an adequate anti-Borrelial drug regimen (e.g. doxycycline) [8].
In immunocompromised patients there are some evidences for a more prolonged anti-Babesia therapy (e.g. more
than  10  days)  to  be  prescribed  [32].  In  patients  severely  ill  with  haemolysis  and  organ  failure  with  high  levels  of
Babesia in blood, transfusions may be sensible [33, 34].
According  to  data  available,  it  seems  that  babesiosis  represents  a  minor  health  hazard  and  can  cause  little
consequence  as  a  co-infection  in  LD  [3].
CONTEMPORARY INFECTION WITH ANAPLASMA PHAGOCITOPHILUM AND BABESIA SPECIES
Bb sensu lato, Anaplasma phagocytophilum and Babesia share very similar epidemiology and trasmission cycles,
having hard ticks as vectors and white-footed mice and white-tailed deer as reservoir hosts [11].
Since Bb, Anaplasma phagocitophilum and Babesia may be co-transmitted by Ixodes ticks bite, the clinical features
of acute and chronic disease can be atypical, complex and variable [10].
In an original study, Krause et al.[10] analysed clinical and laboratory features as well as short-term complications
in 192 people living in New England who experienced infections due to Bb and or Babesia and Ehrlichia. The Authors
found  that  erythema  migrans  is  very  peculiar  of  LD alone,  whereas  flu-like  symptoms  are  more  suggestive  of  LD
concurrent with babesiosis and/or HGA. However, LD itself in small percentage (about 10%) can present with fever,
chills and headache. Such an epidemiologic report is confirmed also in Europe: in an Italian study conducted on more
than  700  people  living  in  an  endemic  area  for  LD,  flu-like  symptoms  as  fever,  myalgia  and  headache  preceded,
accompanied or were the only clinical sign of LD in 16.88% of patients [35].
From the study by Krause et al, it seems that patients having only LD experienced a fewer number of symptoms and
a shorter time of illness compared to those with babesiosis, HGA or co-infection between LD and babesiosis or HGA.
The Authors suggest performing serological laboratory tests for Babesia and Ehrlichia in suspected LD patients having
prolonged flu-like symptoms and poorly responding to an appropriate antiborrelial therapy.
In contrast with other reports [33, 36, 37], Krause et al. found that the presence of a co-infection does not help Bb to
spread more rapidly into blood, skin, joint, nervous system and heart [10].
BARTONELLA SPECIES
Bartonella  species  are  vector-transmitted,  blood-borne,  intracellular,  gram-negative  bacteria  that  can  induce
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prolonged infection in the host. Persistent infections in domestic and wild animals result in a substantial reservoir of
Bartonella organisms in nature that can serve as a source for inadvertent human infection. A wide spectrum of disease
has  been  described  in  immunocompetent  individuals,  including  bacillary  angiomatosis,  peliosis  hepatitis,
lymphadenitis,  and  aseptic  meningitis  with  bacteremia  and  cat-scratch  disease  [4,  38].  Human  bartonellosis  main
features  are  represented  by  infected  skin  lesions  and  lymphadenopathy.  It  can  be  a  multisystemic  disease  with
involvement  of  spleen,  liver,  central  nervous  system  and  eye  [39].
Even if Bartonella henselae has been found in Ixodes ticks in USA, Europe and Russia, there are no proven data in
Literature for a tick-born transission of human bartonellosis [40 - 42].
Bartonella infection can be detected by serologic findings (controversial), PCR amplification (either in blood or in
tissue) and culture (difficult) [4, 43].
The main treatment suggested is azithromycin 500 mg single dose orally on day one, followed by 250 mg every 6
hours for 4 days [44].
RICKETTSIA SPECIES
Ixodes  tick  bites  might  transmit  Rickettsia  species  as  well.  Some Rickettsia  species  are  known to  cause  human
diseases, whereas some others are not fully identified as pathogen to humans [45].
Usually the co-infection between Borrelia and Rickettsia does not represent a diagnostic challenge because the acute
Rickettsia infection is dominated by a typical generalized exanthema, high fever, abdominal symptoms, prostration and
potentially central nervous system impairment.
The main-stray treatment for Rickettsiosis is doxycycline [4].
TICK-BORNE ENCEPHALITIS (TBE)
In endemic areas, TBE and LD are equally transmitted by Ixodes ticks. TBE and neuroborreliosis share common
clinical  features  such  as  lymphocytic  meningitis,  meningomyelitis,  limb  weakness,  cranial  nerve  impairment  [46].
Differentiating between TBE and LD is important because of the different therapeutic approaches.
TBE is a febrile illness, which develops within 1 month after a tick bite and has typically a biphasic course: a flu-
like symptoms prodromic period ranging from 1 to 2 weeks after the tick bite is followed by a 2 to 10 day asymptomatic
period. After that, about one out of three patients experience the second phase of the disease with aseptic meningitis.
Some of them later will develop a post-encephalitis syndrome [47, 48]. In a paper by Logina et al, the Authors focused
on  common  clinical  features  shared  by  LD  and  TBE,  suggesting  that  physician  should  have  a  low-threshold  for
prescribing antibiotics against LD in patients with TBE [44].
Infection by TBE virus can be detected by specific antibody titre in cerebrospinal fluid (ELISA). Serology in this
case is found to be sensitive and specific for the diagnosis [49].
Any specific  antiviral  therapy for  TBE is  not  available  yet.  In  endemic areas,  vaccination against  TBE virus  is
accessible and strongly recommended.
CONCLUSION
In recent years co-infections in LD spectrum represent an emerging issue, even if they are less frequent compared to
the  report  of  micro-organisms  found  in  ticks.  Such  a  problem  is  more  evident  in  endemic  places  with  significant
differences among different geographic areas, according to natural habitat which may foster the vital cycle of pathogen.
Humans, as occasional hosts, may be infected, though concomitant infections with more than two organisms are rarely
reported.
Only a single paper describing four co-infecting pathogens detected in forestry workers in an endemic area can be
found in Literature [50]. The actual role of these infections in asymptomatic people is not unravelled yet, as well as the
possible effect on clinical history of disease; also the therapeutical approach in such cases is not well defined.
LD  is  a  highly  complex  condition  and  still  partially  controversial  as  regards  late  and  chronic  phases.  Possible
explanations to clinical features of such phases have been searched in co-infections in LD, even if studies on adequate
records did not support this hypothesis. In a convincing review Lantos and colleagues’ main purpose was to answer
several questions about the relevance of co-infections in chronic LD; they found that Literature does not sustain the
diagnosis of chronic and atypical co-infections in patients with chronic unspecific LD [7].
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On the other hand, more and more reports of single clinical cases or case series point out the role of co-infections as
worsening or trigger factor in late LD picture. Recently a correlation between cutaneous B-cell lymphomas and Bb has
been supposed [51 - 53]. In our experience, in primitive cutaneous B-cell lymphomas we found that in 100% of cases
the presence of Bb and Anaplasma phagocytophilum could be detected by means of PCR (unpublished data).
In front of such controversies, in endemic areas for tick-borne diseases, it is sensible that co-infections are searched
and noticed especially in potentially exposed people (either for working or for travelling reasons). Prospective studies
on wide records are needed to prove the actual burden of this issue.
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